Abbott Laboratories

Analyst Ratings Synthesis

The supplied consensus is Buy across 20 analysts, with the low, mean, and high price targets all listed at $120, implying no spread in that consensus snapshot. Other supplied forecast pages show materially different aggregate estimates: Fintel lists a $146.85 average and a $123.37–$170.10 range, while Zacks lists a $136.09 average and a $117–$158 range. Those platform-level figures indicate disagreement in published target data, but no named analysts are identified as the most or least bullish. Rothschild & Co upgraded Abbott from Neutral to Buy on October 2, a positive rating revision just after the final supplied close; the evidence does not establish a broader direction of revisions during the week.